Picture Bionordic Nordic Life Science Days 2018 Stockholm 600x60px
Document › Details

Eurofins Scientific. (1/13/16). "Press Release: Eurofins Reinforces Its Market Leadership in Pharmaceutical Products Testing with the Acquisition of Sinensis Life Sciences B.V.". Luxembourg.

Organisations Organisation Eurofins Scientific SE (EUFI.PA)
  Group Eurofins (Group)
  Organisation 2 Sinensis Life Sciences B.V.
  Today Sinensis (Group)
  Group Eurofins (Group)
Products Product quality control diagnostics
  Product 2 analytical services
Persons Person Santing, Ruud (Sinensis 201409 CEO)
  Person 2 Martin, Gilles G. (Eurofins 200701 CEO + founder)

Eurofins Scientific (EUFI.PA), the world leader in pharmaceutical products testing, announces the acquisition of Sinensis Life Sciences B.V. (“Sinensis”), the leading provider of pharmaceutical product testing and cGMP Quality Control (QC) services in the Netherlands.

Sinensis is the reference laboratory for both microbiology and chemistry testing for biopharmaceutical products in the domestic market, and has a presence in Europe, Asia and the US. The company employs about 150 staff, serving the pharmaceutical and biotechnology industries throughout the Netherlands. Since inception, Sinensis has consistently grown well above Eurofins’ annual organic growth objective, and expects to generate revenues in excess of EUR 13.5m for 2015, the majority of which from biopharmaceutical products testing. The company is also active in biosafety testing and biological R&D, chemical R&D, and in cGMP manufacturing.

Sinensis’ competencies are consistent with Eurofins’ market-leading biopharmaceutical testing capabilities, and specifically with the competencies of Eurofins Lancaster, the global reference in biopharmaceutical testing. Therefore, the acquisition strengthens the Group’s geographical footprint and its position as the market leader in this stable and consistently growing pharmaceutical services segment. Furthermore, this acquisition reinforces the Group’s platform to further accelerate the deployment of the most advanced testing methodologies to support the pharmaceutical and biotechnology industries across the entire drug development cycle in Europe.

Sinensis CEO Dr. Ruud Santing ads: “On behalf of all Sinensis shareholders I’m happy that the strong market position that Sinensis and its affiliated companies have generated can be further strengthened within the globally active Eurofins Group.”

Comment from Dr. Gilles Martin, Eurofins CEO: “The acquisition of Sinensis further strengthens Eurofins’ global leadership in the rapidly-growing pharmaceutical products testing market. We look forward to strengthening Sinensis’ testing portfolio and operating footprint by providing access to the full range of services and capabilities of the Eurofins Group.”

Notes for the editor:

Eurofins – a global leader in bio-analysis

Eurofins Scientific is the world leader in food, environment and pharmaceutical products testing. It is also one of the global market leaders in agroscience, genomics, discovery pharmacology and central laboratory services. In addition, Eurofins is one of the key emerging players in specialty clinical diagnostic testing in Europe and the USA.

With over 20,000 staff and 200 laboratories across 39 countries, Eurofins offers a portfolio of over 130,000 reliable analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group provides its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific’ management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantee can be made as to their validity.

For more information, please visit or contact:

Eurofins Investor Relations
+32-2-766 1620

Record changed: 2016-01-13


Picture [LSE] – The Business Web Portal 600x80px

More documents for Eurofins (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture Bionordic Nordic Life Science Days 2018 Stockholm 600x60px

» top